GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCF) » Definitions » Gross Profit

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Gross Profit : $4,815 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Chugai Pharmaceutical Co Gross Profit?

Chugai Pharmaceutical Co's gross profit for the three months ended in Mar. 2024 was $1,095 Mil. Chugai Pharmaceutical Co's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $4,815 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Chugai Pharmaceutical Co's gross profit for the three months ended in Mar. 2024 was $1,095 Mil. Chugai Pharmaceutical Co's Revenue for the three months ended in Mar. 2024 was $1,582 Mil. Therefore, Chugai Pharmaceutical Co's Gross Margin % for the quarter that ended in Mar. 2024 was 69.21%.

Chugai Pharmaceutical Co had a gross margin of 69.21% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Chugai Pharmaceutical Co was 67.67%. The lowest was 49.58%. And the median was 57.94%.


Chugai Pharmaceutical Co Gross Profit Historical Data

The historical data trend for Chugai Pharmaceutical Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Gross Profit Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,850.68 4,947.06 5,812.13 5,807.18 4,848.27

Chugai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,203.84 1,243.34 1,215.07 1,262.33 1,094.65

Competitive Comparison of Chugai Pharmaceutical Co's Gross Profit

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Gross Profit falls into.



Chugai Pharmaceutical Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Chugai Pharmaceutical Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=7718.818 - 2870.549
=4,848

Chugai Pharmaceutical Co's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=1581.573 - 486.923
=1,095

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,815 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Chugai Pharmaceutical Co's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=1,095 / 1581.573
=69.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Chugai Pharmaceutical Co  (OTCPK:CHGCF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Chugai Pharmaceutical Co had a gross margin of 69.21% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Chugai Pharmaceutical Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines